Immunovia AB (publ) (IMMVF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Immunovia AB (publ) (IMMVF) trades at $0.02 with AI Score 39/100 (Grade D). Immunovia AB (publ) is a diagnostic company focused on early detection of cancer through blood-based tests. Market cap: $6.11M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for IMMVF: IMMVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMMVF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMMVF: 1/1 perspectives are bearish.
How is this calculated? →Immunovia AB (publ) (IMMVF) Healthcare & Pipeline Overview
Immunovia AB (publ) develops and commercializes blood-based diagnostic tests, primarily IMMray PanCan-d for early pancreatic cancer detection, operating in the competitive medical diagnostics market with a focus on international expansion and lung cancer research projects, while facing financial challenges reflected in negative profit margins.
What Is the Investment Thesis for IMMVF?
Immunovia AB (publ) presents a high-risk, high-reward investment opportunity centered on its IMMray PanCan-d test for early pancreatic cancer detection. The potential value driver is the successful commercialization and adoption of IMMray PanCan-d, addressing a critical unmet need in cancer diagnostics. Key catalysts include positive clinical trial results, regulatory approvals, and successful market penetration in key geographic regions. However, the company's negative profit margin of -21332.5% and gross margin of -2337.6% highlight significant financial challenges. The company's future hinges on securing additional funding and achieving profitability. Investors should closely monitor the company's cash burn rate, revenue growth, and competitive landscape.
Based on FMP financials and quantitative analysis
IMMVF Key Highlights
- Market capitalization of $6.11M, indicating a micro-cap company with significant growth potential but also higher risk.
- P/E ratio of -0.58, reflecting current losses and the company's focus on growth and future profitability.
- Profit Margin of -21332.5%, highlighting the company's current financial struggles and the need for improved cost management and revenue generation.
- Gross Margin of -2337.6%, indicating challenges in the cost of goods sold and pricing strategies.
- Beta of 2.77, suggesting high volatility compared to the overall market, reflecting the speculative nature of the stock and its sensitivity to market fluctuations.
Who Are IMMVF's Competitors?
IMMVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANPCY CelLBxHealth plc | $0.07 | +0.00% | $21.98M | 55 |
| ASAPF Aurora Spine Corporation | $0.17 | +1.85% | $13.32M | 48 |
| CLCS Cell Source, Inc. | $0.87 | -5.97% | $39.39M | 45 |
| OPGN OpGen, Inc. | $23.91 | +64.36% | $242.67M | 63 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMMVF's Key Strengths?
- Proprietary IMMray PanCan-d test for early pancreatic cancer detection.
- Focus on a critical unmet need in cancer diagnostics.
- Expertise in proteomics and biomarker discovery.
- International operations.
What Are IMMVF's Weaknesses?
- Negative profit and gross margins.
- Small company size with limited resources.
- Reliance on a single product (IMMray PanCan-d).
- Limited market penetration.
What Could Drive IMMVF Stock Higher?
- Positive results from ongoing clinical trials of IMMray PanCan-d.
- Expansion of commercial operations into new geographic markets.
- Development of new diagnostic tests for other cancers.
- Strategic partnerships and collaborations with pharmaceutical companies and healthcare providers.
What Are the Key Risks for IMMVF?
- Financial-distress signal — its Altman Z-Score of -27.96 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from established diagnostics companies.
- Regulatory hurdles and approval processes for diagnostic tests.
- Reimbursement challenges from healthcare payers.
- Negative profit and gross margins, requiring additional funding.
- Technological advancements and disruptive innovations in cancer diagnostics.
What Are the Growth Opportunities for IMMVF?
- Expansion into New Geographic Markets: Immunovia has the opportunity to expand its commercial operations into new geographic markets, particularly in regions with high pancreatic cancer incidence rates and unmet diagnostic needs. This expansion could involve establishing partnerships with local distributors, conducting clinical trials in new regions, and obtaining regulatory approvals in new countries. Successful geographic expansion could significantly increase Immunovia's revenue and market share. Timeline: Ongoing.
- Development of New Diagnostic Tests: Immunovia can leverage its expertise in proteomics and biomarker discovery to develop new diagnostic tests for other types of cancer and diseases. This diversification of its product portfolio would reduce its reliance on IMMray PanCan-d and create new revenue streams. The company's research projects focused on lung cancer represent a potential first step in this direction. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Immunovia can pursue strategic partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare providers to accelerate the development and commercialization of its diagnostic tests. These partnerships could provide access to funding, expertise, and distribution channels. For example, a partnership with a pharmaceutical company developing a new pancreatic cancer drug could help to drive adoption of IMMray PanCan-d. Timeline: Ongoing.
- Increased Awareness and Adoption of IMMray PanCan-d: Immunovia can invest in marketing and educational initiatives to increase awareness and adoption of IMMray PanCan-d among physicians and patients. This could involve presenting clinical data at medical conferences, publishing articles in peer-reviewed journals, and conducting direct-to-consumer advertising campaigns. Increased awareness and adoption of IMMray PanCan-d would drive revenue growth and improve patient outcomes. Timeline: Ongoing.
- Leveraging AI and Machine Learning: Immunovia can integrate artificial intelligence (AI) and machine learning (ML) technologies into its diagnostic development process to improve the accuracy and efficiency of its tests. AI/ML can be used to identify new biomarkers, optimize test algorithms, and personalize diagnostic results. This would enhance the value proposition of Immunovia's tests and give it a competitive advantage. Timeline: Ongoing.
What Opportunities Does IMMVF Have?
- Expansion into new geographic markets.
- Development of new diagnostic tests for other cancers.
- Strategic partnerships and collaborations.
- Increased awareness and adoption of IMMray PanCan-d.
What Threats Does IMMVF Face?
- Competition from established diagnostics companies.
- Regulatory hurdles and approval processes.
- Technological advancements and disruptive innovations.
- Reimbursement challenges from healthcare payers.
What Are IMMVF's Competitive Advantages?
- Proprietary IMMray PanCan-d test.
- Expertise in proteomics and biomarker discovery.
- Focus on early cancer detection.
- Research projects for lung cancer.
What Does IMMVF Do?
Immunovia AB (publ), established in 2007 and headquartered in Lund, Sweden, is a diagnostic company dedicated to the development and commercialization of innovative blood tests. The company's flagship product, IMMray PanCan-d, is a blood-based test designed for the early detection of pancreatic cancer, a disease known for its aggressive nature and poor prognosis when diagnosed late. Immunovia's mission is to improve survival rates and quality of life for patients by enabling earlier diagnosis and treatment interventions. Beyond pancreatic cancer, Immunovia is also engaged in research projects focused on lung cancer, indicating a broader ambition to expand its diagnostic capabilities across multiple cancer types. The company operates both in Sweden and internationally, reflecting its commitment to making its diagnostic solutions accessible to patients worldwide. Immunovia's business model centers around the development, validation, and commercialization of proprietary diagnostic tests, leveraging its expertise in proteomics and biomarker discovery. The company faces competition from established players in the diagnostics industry, as well as emerging companies developing novel cancer detection technologies. With a small team of 9 employees, Immunovia operates with a lean structure, focusing its resources on research, development, and commercialization efforts.
What Products and Services Does IMMVF Offer?
- Develop blood-based diagnostic tests.
- Focus on early detection of pancreatic cancer.
- Commercialize IMMray PanCan-d test.
- Conduct research projects for lung cancer.
- Operate in Sweden and internationally.
- Aim to improve survival rates for cancer patients.
How Does IMMVF Make Money?
- Develop proprietary diagnostic tests.
- Commercialize tests through direct sales and partnerships.
- Generate revenue from test sales.
- Invest in research and development for new tests.
What Industry Does IMMVF Operate In?
Immunovia operates in the medical diagnostics industry, a sector experiencing rapid growth driven by technological advancements and increasing demand for early and accurate disease detection. The market for cancer diagnostics is particularly large and growing, fueled by an aging population and rising cancer incidence rates. Immunovia's focus on early pancreatic cancer detection positions it within a niche segment of this market. Competitors include companies developing liquid biopsy tests and other diagnostic modalities. The industry is characterized by intense competition, stringent regulatory requirements, and the need for continuous innovation.
Who Are IMMVF's Key Customers?
- Hospitals and clinics.
- Physicians and oncologists.
- Patients at risk of pancreatic cancer.
- Healthcare providers.
FY2026 estForward Outlook
Wall Street analysts project Immunovia AB (publ) revenue of about $3.0M for fiscal 2026, with EPS near $-0.10.
Key Financial Metrics
A current ratio of 3.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -82.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Immunovia AB (publ)'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -27.96 places it in the distress zone, a signal of elevated financial risk.
IMMVF Valuation & Market Position
With a $6.11M market cap, Immunovia AB (publ) sits in the micro-cap segment of the market. Relative to its peer group, IMMVF's quantitative score of 39/100 is below the peer average of 56/100.
IMMVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insiders seem to be accumulating shares, which often signals confidence in the company's future prospects.
- The community is buzzing about potential breakthroughs in early cancer detection, driving positive sentiment around Immunovia's technology.
- Recent market developments suggest increased investor interest in innovative diagnostic solutions, potentially benefiting IMMVF.
- Bullish voices in the community highlight the unmet need for early pancreatic cancer detection and Immunovia's potential to address it.
Bear Case
- Community discussions reveal concerns about the speed of commercialization and market adoption of Immunovia's tests.
- Bearish sentiment focuses on the competitive landscape, with questions about Immunovia's ability to stand out.
- Recent insider activity also includes some selling, which could indicate a lack of complete confidence or portfolio rebalancing.
- Market perception reflects some skepticism about the scalability of Immunovia's technology and its long-term profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
IMMVF Latest News
No recent news available for IMMVF.
IMMVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMMVF.
Price Targets
Wall Street price target analysis for IMMVF.
IMMVF MoonshotScore
What does this score mean?
The MoonshotScore rates IMMVF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jeff Borcherding
CEO
Jeff Borcherding serves as the CEO of Immunovia AB (publ). Information regarding his detailed career history, education, and previous roles is not available in the provided data. As the CEO, he is responsible for leading the company's strategic direction, overseeing its operations, and driving its growth initiatives. He manages a team of 9 employees.
Track Record: Information regarding Jeff Borcherding's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. His tenure at Immunovia AB (publ) cannot be determined from the given information.
IMMVF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Immunovia AB (publ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be subject to limited regulatory oversight and may not provide comprehensive financial disclosures. Investing in companies on the OTC Other tier carries a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and trading volume.
- Lack of regulatory oversight and transparency.
- Potential for price manipulation and fraud.
- Higher risk of financial distress or bankruptcy.
- Limited access to information and research.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any history of regulatory issues or red flags.
- Company has been in operation since 2007.
- Focus on developing diagnostic tests for cancer.
- Commercializing IMMray PanCan-d test.
- Presence of a CEO (Jeff Borcherding).
What Investors Ask About Immunovia AB (publ) (IMMVF) — Healthcare
What does Immunovia AB (publ) do?
Immunovia AB (publ) is a diagnostic company that develops and commercializes blood-based tests for the early detection of cancer, with a primary focus on pancreatic cancer. Its flagship product, IMMray PanCan-d, is designed to detect pancreatic cancer at an early stage, improving patient outcomes. The company also conducts research projects for lung cancer, indicating a broader ambition to expand its diagnostic capabilities. Immunovia operates in Sweden and internationally, aiming to make its diagnostic solutions accessible to patients worldwide.
What are the main risks for IMMVF?
The main risks for Immunovia AB (publ) include intense competition from established diagnostics companies, regulatory hurdles and approval processes for its diagnostic tests, and potential reimbursement challenges from healthcare payers. The company's negative profit and gross margins also pose a significant risk, requiring it to secure additional funding to sustain its operations. Additionally, technological advancements and disruptive innovations in cancer diagnostics could render its products obsolete.
How does Immunovia AB (publ) manage patent expiration risks?
As a diagnostic company, Immunovia AB (publ) faces risks associated with patent protection for its IMMray PanCan-d test and other diagnostic technologies. While specific details on their patent portfolio are unavailable, the company likely employs strategies such as filing patents on novel biomarkers, test algorithms, and methods of use. Managing patent expiration involves continuously innovating and developing new diagnostic solutions to maintain a competitive edge and protect its intellectual property. The company must also monitor the competitive landscape for potential patent infringement and be prepared to defend its patents if necessary.
What revenue streams does Immunovia AB (publ) have in healthcare?
Immunovia AB (publ)'s primary revenue stream is currently derived from the commercialization of its IMMray PanCan-d test for early pancreatic cancer detection. While specific revenue figures are not provided, the company generates income from the sale of this test to hospitals, clinics, and healthcare providers. As Immunovia expands its product portfolio and geographic reach, it anticipates diversifying its revenue streams through the introduction of new diagnostic tests and the establishment of partnerships with pharmaceutical companies and research institutions. The success of these efforts will be crucial for the company's long-term financial sustainability.
What are the key factors to evaluate for IMMVF?
Immunovia AB (publ) (IMMVF) holds an AI score of 39/100 (low). Not financial advice.
How frequently does IMMVF data refresh on this page?
IMMVF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IMMVF's recent stock price performance?
Immunovia AB (publ) (IMMVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary IMMray PanCan-d test for early pancreatic cancer detection. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMMVF overvalued or undervalued right now?
Valuing Immunovia AB (publ) (IMMVF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available.
- OTC market investments are highly speculative.